Skip to content

Clinical efficacy of Xuefu Zhuyu Capsule combined with clopidogrel in the treatment of coronary heart disease after PCI for one year

Clinical efficacy of Xuefu Zhuyu Capsule combined with clopidogrel in the treatment of coronary heart disease after PCI for one year

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002602
Enrollment
Unknown
Registered
2019-09-17
Start date
2019-09-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Sponsors

The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Coronary angiography showed that at least one coronary artery stenosis was more than 50%, but less than 75%. For those who did not receive PCI or received PCI, the indications of PCI were in accordance with the Chinese Medical Association Guidelines for Percutaneous Coronary Intervention (2016). Binary antiplatelet therapy was standardized after 1 year. (2) Subjects were informed and voluntarily signed the informed consent. (Note: Only those who meet the requirements of the above two items can be enrolled in the group.)

Exclusion criteria

Exclusion criteria: (1) Anti-platelet drug allergy or intolerance; (2) Having hematological diseases or malignant tumors; (3) There are active peptic ulcer and major surgical operations recently. (4) Severe heart failure, severe liver and kidney dysfunction; (5) History of stroke in the past; (6) Severe cardiovascular or hemorrhagic events occurred within 1 year after PCI. (7) Patients unwilling to continue receiving antiplatelet therapy after 12 months of dual antiplatelet therapy; (8) those who are known to be allergic to the ingredients of the drug; (9) Mental and neurological disorders; (10) A similar experiment of traditional Chinese medicine has been done in the past three months. (Note: The same subject can not be re-entered into the same clinical trial, and those who meet any of the above criteria can not be included)

Design outcomes

Primary

MeasureTime frame
General situation;Angina symptom score;Seattle Angina Inventory Scale;Curative effect of TCM symptoms;

Countries

China

Contacts

Public ContactZhao Yingqiang

The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

zhaoyingqiang1000@126.com+86 13920089969

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026